EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Assessing the risk of cervical neoplasia in the post‐HPV vaccination era

Matti Lehtinen iD, Ville N Pimenoff iD, Belinda Nedjai, Karolina Louvanto, Lisanne Verhoef iD, Daniëlle A M Heideman, Mariam El-Zein, Martin Widschwendter, Joakim Dillner iD

International Journal of Cancer · 2023-03-15 · 152 (6) · 1060-1068

DOI: 10.1002/ijc.34286 ↗

At a glance

Übersichtsarbeit in International Journal of Cancer, published online on 2022-10-10. Written by Matti Lehtinen and 8 co-authors. Institution: Medical Faculty, Tampere University, Tampere, Finland. Major MEDLINE topics: Uterine Cervical Neoplasms, Papillomavirus Infections, Uterine Cervical Dysplasia, Papillomavirus Vaccines. Cited 33 times so far (Crossref); 77 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Cancer Research UK.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

This review is based on the recent EUROGIN scientific session: “Assessing risk of cervical cancer in the post‐vaccination era,” which addressed the demands of cervical intraepithelial neoplasia (CIN)/squamous intraepithelial lesion (SIL) triage now that the prevalence of vaccine‐targeted oncogenic high‐risk (hr) human papillomaviruses (HPVs) is decreasing. Change in the prevalence distribution of oncogenic HPV types that follows national HPV vaccination programs is setting the stage for loss of positive predictive value of conventional but possibly also new triage modalities. Understanding the contribution of the latter, most notably hypermethylation of cellular and viral genes in a new setting where most oncogenic HPV types are no longer present, requires studies on their performance in vaccinated women with CIN/SIL that are associated with nonvaccine HPV types. Lessons learned from this research may highlight the potential of cervical cells for risk prediction of all women's cancers.

Subjects

MeSH terms (MEDLINE)

Uterine Cervical NeoplasmsPapillomavirus InfectionsUterine Cervical DysplasiaPapillomavirus VaccinesFemaleHumansPredictive Value of TestsVaccinationPapillomaviridae

Author keywords

cervical cancerepigeneticsgynecological cancershuman papillomavirusmethylation

Substances

Papillomavirus Vaccines

Authors and institutions

  • Medical Faculty, Tampere University, Tampere, Finland.
  • Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
  • Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
  • Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland.
  • Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.

ORCID profiles: Matti Lehtinen, Ville N Pimenoff, Lisanne Verhoef, Joakim Dillner

Funding

  • Cancer Research UK

Cite

APA

Lehtinen, M., Pimenoff, V. N., Nedjai, B., Louvanto, K., Verhoef, L., Heideman, D. A. M., El-Zein, M., Widschwendter, M., & Dillner, J. (2023). Assessing the risk of cervical neoplasia in the post‐HPV vaccination era. International Journal of Cancer, 152(6), 1060-1068. https://doi.org/10.1002/ijc.34286

Vancouver

Lehtinen M, Pimenoff VN, Nedjai B, Louvanto K, Verhoef L, Heideman DAM, et al. Assessing the risk of cervical neoplasia in the post‐HPV vaccination era. International Journal of Cancer. 2023;152(6):1060-1068. doi:10.1002/ijc.34286

BibTeX
@article{Lehtinen2023,
  author = {Lehtinen, Matti and Pimenoff, Ville N and Nedjai, Belinda and Louvanto, Karolina and Verhoef, Lisanne and Heideman, Daniëlle A M and El-Zein, Mariam and Widschwendter, Martin and Dillner, Joakim},
  title = {Assessing the risk of cervical neoplasia in the post‐HPV vaccination era},
  journal = {International Journal of Cancer},
  year = {2023},
  volume = {152},
  number = {6},
  pages = {1060--1068},
  doi = {10.1002/ijc.34286}
}
Start for free →